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http://dx.doi.org/10.1016/j.jacl.2015.04BACKGROUND: Lipoprotein(a) (Lp(a)) is a proatherogenic plasma lipoprotein currently established
as an independent risk factor for the development of atherosclerotic disease and as a predictor for acute
thrombotic complications. In addition, Lp(a) is the major carrier of proinflammatory oxidized phospho-
lipids (OxPL). Today, atherosclerosis is considered to be an inflammatory disease of the vessel wall in
which monocytes and monocyte-derived macrophages are crucially involved. Circulating monocytes
can be divided according to their surface expression pattern of CD14 and CD16 into at least 3 subsets
with distinct inflammatory and atherogenic potential.
OBJECTIVE: The aim of this study was to examine whether elevated levels of Lp(a) and OxPL on
apolipoprotein B-100–containing lipoproteins (OxPL/apoB) are associated with changes in monocyte
subset distribution.
METHODS: We included 90 patients with stable coronary artery disease. Lp(a) and OxPL/apoB were
measured, and monocyte subsets were identified as classical monocytes (CMs; CD1411CD162), inter-
mediate monocytes (IMs; CD1411CD161), and nonclassical monocytes (NCMs; CD141CD1611)
by flow cytometry.
RESULTS: In patients with elevated levels of Lp(a) (.50 mg/dL), monocyte subset distribution was
skewed toward an increase in the proportion of IM (7.0 6 3.8% vs 5.2 6 3.0%; P 5 .026), whereas CM
(82.6 6 6.5% vs 82.0 6 6.8%; P 5 .73) and NCM (10.5 6 5.3 vs 12.8 6 6.0; P 5 .10) were notF Austrian Science Fund (Grant
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534 Journal of Clinical Lipidology, Vol 9, No 4, August 2015significantly different. This association was independent of clinical risk factors, choice of statin treatment
regime, and inflammatory markers. In addition, OxPL/apoB was higher in patients with elevated Lp(a)
and correlated with IM but not CM and NCM.
CONCLUSIONS: In conclusion, we provide a potential link between elevated levels of Lp(a) and a
proatherogenic distribution of monocyte subtypes in patients with stable atherosclerotic disease.
 2015 National Lipid Association. This is an open access article under the CC BY license (http://
creativecommons.org/licenses/by/4.0/).Introduction
Despite major advances in vascular medicine including
high-dose statin treatment, cardiovascular diseases remain
the leading cause of death in the Western world.1 Lipopro-
tein(a) (Lp(a)) is a plasma lipoprotein that consists of a
cholesterol-rich, low-density lipoprotein (LDL)-like parti-
cle and an additional protein apolipoprotein(a), which is
covalently bound to the ApoB of the LDL-like particle.2,3
Today it is established as an independent risk factor for
the development of stable ischemic disease and myocardial
infarction.2–4 Genetic studies suggest causality; however,
mechanistic insights are scarce.5,6 The European Athero-
sclerosis Society suggests to measure Lp(a) in all interme-
diate or high-risk patients and advises a desirable level of
less than 50 mg/dL (,80th percentile).2
Monocytes are crucially involved in practically all
stages of atherogenesis as the cellular drivers of vascular
inflammation hallmarking atherosclerotic disease.7,8 Mono-
cytes represent a heterogeneous cell population, reflected
by their differential surface expression pattern of CD14
and CD16.9 CD16-positive monocytes account for more
than 10% of all monocytes and were soon suggested to
be proinflammatory cells characterized by a pronounced
inflammatory answer on stimulation.10,11 Furthermore, the
proportion of these cells was expanded in various inflam-
matory diseases, including a mixed patient cohort with cor-
onary artery disease (CAD).12 Accumulating evidence
suggested a further division of CD16-positive cells into 2
subtypes of cells, which was finally officially acknowl-
edged in a consensus article under the auspices of the
Nomenclature Committee of the International Union of
Immunological Societies proposing the following classifi-
cation: CD1411CD162 (classical monocytes [CMs]),
CD1411CD161 (intermediate monocytes [IMs]), and
CD141CD1611 (nonclassical monocytes [NCMs]).13
CD16-positive monocytes were shown to correlate with
body mass index and intima media thickness in apparently
healthy adults and were associated with plaque phenotype
in patients with both, stable and unstable, atherosclerotic
disease.14–16 NCMs correlated with total cholesterol (TC)
and triglycerides, whereas a negative association with
high-density lipoprotein (HDL) levels was shown.17,18
The largest study evaluating monocyte subset distribution
as a biomarker for cardiovascular disease prediction in
more than 900 stable CAD patients showed that an
increased proportion of IM was associated with increased
cardiovascular events.19Lp(a) is the major carrier of oxidized phospholipids
(OxPL) that have been shown to act proinflammatory and
to activate monocytes.20 Insights into the mechanism
shifting monocyte subset distribution toward a more
proinflammatory distribution are limited. The aim of
this study was therefore to investigate whether patients
with stable CAD at high cardiovascular risk evidenced
by elevated Lp(a) levels show a shift in monocyte
subset distribution toward a proatherogenic profile and
whether monocyte subset distribution is associated with
OxPL on apolipoprotein B-100–containing lipoproteins
(OxPL/apoB).Methods
Subjects and study design
Between September 2009 and April 2010, we included
all consecutive patients with stable CAD admitted to the
General Hospital of Vienna for elective coronary angio-
graphy. The study complies with the Declaration of
Helsinki and was approved by the ethical committee of
the Medical University of Vienna. All patients, female and
male, aged older than 18 y with stable CAD who gave
written consent were included in this study. To avoid any
impact of recent acute inflammatory conditions, we
excluded patients who experienced a recent acute coronary
syndrome, defined as ST-elevating myocardial infarction,
non–ST-elevating myocardial infarction, or unstable
angina with or without undergoing percutaneous coronary
intervention within the last 3 mo. Further exclusion criteria
consisted of heart failure, valvular disease, malignant
disease, liver, kidney or other acute or chronic inflamma-
tory diseases.
Arterial hypertension was defined as systolic blood
pressure $140 mm Hg and diastolic blood pressure
$90 mm Hg in at least 2 measurements or the current
use of antihypertensive drugs. Patients were considered to
be diabetic if treated for insulin or noninsulin-dependent
diabetes mellitus or having a plasma fasting glucose
$126 mg/dL in at least 2 measurements or having a
glycated hemoglobin fraction of $6.5%. Statin treatment
was noted, and treatment with atorvastatin with a dosage of
at least 40 mg or rosuvastatin at a dosage of at least 10 mg
daily was defined as moderate-to-high dose statin treat-
ment. CAD extent is given as the number of epicardial
coronary arteries with a $70% stenosis.
Figure 1 Gating strategy used for monocyte subset discrimination. Monocytes were defined as CD45 positive cells (B) exhibiting a
typical forward (FSC) and sideward scatter (SSC) profile (A). To exclude possible contamination with T-cells, B-cells, and natural killer
cells, cells that stained for CD3, CD19, and CD56 were excluded, respectively (C). Remaining CD451CD3/19/56– cells with a typical
FSC/SSC profile were considered monocytes and distinguished according to their CD14 and CD16 surface expression into classical
monocytes (CMs; CD1411CD162), intermediate monocytes (IMs; CD1411CD161), and nonclassical monocytes (NCMs;
CD141CD1611) (D).
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To exclude effects of angioplasty on monocyte subset
distribution and any diurnal variation, blood was drawn in
the morning before coronary angiogram. A 21-gauge
butterfly needle (0.8 mm ! 19 mm; Greiner Bio-One,
Kremsm€unster, Austria) was used for venipuncture from an
antecubital vein. The initial 3 mL of blood were discarded,
and blood was drawn into an EDTA tube (Greiner Bio-One)
for immediate analysis by flow cytometry. An additional
3.8% sodium citrate Vacuette tube, a serum separator tube
and an EDTA tube (all Greiner Bio-One) were collected,
centrifuged at 3000 rpm at 4C for 15 min and stored in
aliquots at -80C for later analysis.
Flow cytometry
Whole blood flow cytometry for the determination of
leukocyte and monocyte subset distribution was performed
using a FACS Canto II with the FACS Diva Software (both
Becton Dickinson). The staining and gating strategy is
outlined in Figure 1 and was described previously.21
Briefly, 100 mL of EDTA-anticoagulated whole blood
was stained with saturating concentrations of the following
fluorochrome-conjugated monoclonal antibodies (mAbs):
peridinin chlorophyll protein–labeled mAb for CD45
(Beckton Dickinson, catalog number 345809), fluoresceinisothiocyanate–labeled mAb for CD14 (Beckton Dickin-
son, catalog number 345784), allophycocyanin-H7–labeled
mAb for CD16 (Beckton Dickinson, catalog number
560195), allophycocyanin-labeled mAb for CD3 (Beckton
Dickinson, catalog number 345767), CD19 (Beckton Dick-
inson, catalog number 345791), and CD56 (Beckton Dick-
inson, catalog number 341027) and corresponding isotype
controls. After incubation for 15 min in the dark, 1.5 mL
lysing solution (BD FACS lysing solution BD Biosciences)
was added. After an additional 15 min of incubation in
darkness, cells were washed 3 times by adding 1 mL
phosphate-buffered saline and centrifugation at 820 rpm
for 5 min each. Cells were then resuspended in 1 mL fixa-
tive solution (FACS Flow, reagent-grade water and BD
Cellfix) for FACS-analysis. Monocytes were identified as
CD45-positive and CD3-, CD19-,and CD56-negative cells
exhibiting a specific forward and sideward scatter profile.
Individual monocyte subsets were defined according to
a recently published international consensus document
as ‘‘classical monocytes’’ (CM; CD1411CD162), ‘‘inter-
mediate monocytes’’ (IM; CD1411CD161), and
‘‘nonclassical monocytes’’ (NCM; CD141CD1611).
Absolute numbers of monocytes were calculated using
leukocyte count as determined by the central laboratory
and counts of CD451 cells as determined by flow cytom-
etry. The coefficient of variation for relative monocyte
count was 4.9%.
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For all lipid measurements, only previously unthawed
serum samples were used. Levels of TC (coefficient of
variation [CV], 1.4%22), HDL cholesterol (C.V., between
5% and 6%23), and triglycerides(C.V., 1.3%) were
measured by the general laboratory of Krankenanstalten
Dr. Dostal using enzymatic methods. LDL cholesterol
was calculated using the Friedewald formula when triglyc-
erides were ,400 mg/dL and measured directly when
triglycerides were $400 mg/dL (C.V., 1.7%24). Lp(a) was
measured by an isoform-insensitive immunonephelometric
assay (Roche Diagnostics, Germany; intra-assay C.V.
ranging from 0.9% to 6.2%) that measures apo(a) protein
mass.
Measurement of OxPL on apolipoprotein
B-100–containing lipoproteins
OxPL/apoB was measured in EDTA plasma using the
murine mAb antibody E06 that recognizes the phosphocho-
line group on oxidized but not on native phospholipids. A
1:100 dilution of plasma in phosphate-buffered saline is
added to microtiter wells coated with mAb MB47, which
binds a saturating amount of apoB-100 to each well.
Finally, biotinylated E06 is used to determine OxPL/apoB
in relative light units (RLUs).25 The intra-assay coefficient
of variation was shown to range from 6% to 10%.26
Measurements of cytokines and standard
laboratory markers
Interleukin-6 (IL-6) was measured using a specific
enzyme-linked immunosorbent assay (ELISA; Human
IL-6 Quantikine high-sensitivity ELISA Kit, R&D Sys-
tems, Minneapolis, MN) with a lower limit of detection of
0.016 pg/mL. The intra-assay coefficient of variation ranges
from 6.9% to 7.4%, and the inter-assay coefficient of
variation ranges from 6.5% to 9.6%. Plasma levels of IL-10
were quantified using a customized multiplex assay
(Luminex Assay, R&D Systems) with a lower limit of
detection 0.07 pg/mL. The intra-assay coefficient of
variation ranges from 3.8% to 7.3%, and the inter-assay
coefficient of variation ranges from 5.1% to 12.5%. For the
determination of standard laboratory markers, including
high-sensitive C-reactive protein (CRP; C.V., 2.7%27),
blood was analyzed in the central laboratory of the General
Hospital of Vienna.
Statistical analysis
Categorical variables are expressed as counts or
percentages and were compared by the c2 or by the
Fisher exact test where appropriate. Continuous variables
are given as mean 6 standard deviation or median (inter-
quartile range [IQR]). Parametric data were compared us-
ing the unpaired Student t test, whereas skewed data(assessed by the Kolmogorov–Smirnov test) were
compared by the Mann–Whitney U test. Correlations
were calculated using Pearson’s correlation coefficient
after log-transformation of skewed data. Multivariate
linear regression models were calculated for circulating
IMs. Clinical characteristics or lipid parameters were
added to the model when they were associated with IM
by a P value , .2. In addition, we added age and statin
treatment. We also calculated stepwise multivariate linear
regression models including Lp(a) and the inflammatory
markers CRP, IL-6, and IL-10, respectively. A value of
P , .05 (2-tailed) was considered statistically significant.
All statistical analyses were performed with the Predic-
tive Analysis SoftWare PASW Statistics 18.0 (IBM, Ar-
monk, NY).Results
Patient characteristics
The clinical characteristics of the population studied are
given in Table 1. Patients were aged 64.1 6 9.0 y, 80%
were male, 89% had hypertension, 30% were diagnosed
for having diabetes mellitus, and 23% were current
smokers. All patients had angiographically proven CAD,
28% had single-vessel disease, 40% demonstrated 2
diseased vessels, and 32% had 3-vessel disease. Concerning
lipid-lowering treatment, 31% of patients received
moderate-to-high dose statin, 52% low-dose statin, whereas
17% of patients received no statin treatment. According to
current guidelines,2 21 patients (23%) had elevated levels
of Lp(a) (.50 mg/dL), whereas 69 patients (77%) had
normal levels of Lp(a) (#50 mg/dL). Patients with
increased Lp(a) levels showed no differences in CAD
severity (P 5 .34); however, they showed a definite trend
to be younger compared with patients with normal Lp(a)
levels (61.0 6 9.7 vs 65.1 6 9.1 y; P 5 .08). Furthermore,
there were no differences in demographics, risk factors, or
lipid levels (Table 1).
Association of Lp(a) serum levels and monocyte
subsets
Monocyte subset distribution was determined by flow
cytometry (Fig. 1). Mean number of CMs was 270.56 142.7
cells/mL (82.1 6 6.7% of total monocytes), mean number of
circulating NCMs was 39.76 28.9 cells/mL (12.36 5.9% of
total monocytes), and mean number of IMs was 18.7 6 15.1
cells/mL (5.6 6 3.3% of total monocytes). Patients with
elevated Lp(a) showed a significantly higher proportion of
circulating IM as compared with patients with normal
Lp(a) levels (7.0 6 3.8% vs 5.2 6 3.0%; P 5 .026). In
contrast, distribution of CMs (82.6 6 6.5% vs
82.0 6 6.8%; P 5 .73) and NCMs (10.5 6 5.3 vs
12.8 6 6.0; P 5 .10) was similar in patients with
Lp(a) .50 mg/dL and Lp(a) #50 mg/dL (Fig. 2). Linear
Table 1 Clinical characteristics of the population studied
Parameter Total (n 5 90)
Lp(a) #50 mg/dL
(n 5 69)
Lp(a) .50 mg/dL
(n 5 21) P value
Lp(a) (mg/dL) 14.4 (8.3–48.5) 10.3 (6.6–18.8) 77.3 (61.0–95.2) —
Age (y) 64.1 6 9.0 65.1 6 9.1 61 6 9.7 .08
Male gender, n (%) 72 (80) 56 (81.2) 16 (76.2) .62
Hypertension, n (%) 80 (89) 59 (85.5) 21 (100) .06
Diabetes mellitus, n (%) 27 (30) 21 (30.4) 6 (28.6) .87
Current smoker, n (%) 21 (23.3) 15 (21.7) 6 (28.6) .52
CAD extent (VD) .34
1 VD, n (%) 25 (28) 18 (26.1) 7 (33.3)
2 VD, n (%) 36 (40) 26 (37.7) 10 (47.6)
3 VD, n (%) 29 (32) 25 (36.2) 4 (19)
Statin treatment .87
No statin, n (%) 15 (17) 12 (17.4) 3 (14.3)
Low-dose statin, n (%) 47 (52) 35 (50.7) 12 (57.1)
Moderate-to-high dose statin, n (%) 28 (31) 22 (31.9) 6 (28.6)
BMI (kg/m2) 29 6 4.7 28.9 6 4.4 29.5 6 5.6 .65
HbA1c (%) 6.1 6 0.9 6.0 6 0.8 6.4 6 1.2 .89
Creatinine (mg/dL) 1.1 6 0.3 1.1 6 0.3 1.0 6 0.2 .16
Leukocytes (g/L) 7.1 6 1.7 7.1 6 1.8 7.0 6 1.6 .93
Triglycerides (mg/dL) 130 (103–176) 131 (101–172) 126 (108–180) .92
Total cholesterol (mg/dL) 164.6 6 39 163.2 6 38.4 169.2 6 41.8 .54
HDL (mg/dL) 40.1 6 13.4 40.6 6 13.2 41.6 6 14.4 .77
VLDL (mg/dL) 28.6 6 9.4 28.4 6 10.0 29.1 6 7.2 .75
Non-HDL (mg/dL) 123.7 6 36.4 122.5 6 36.3 127.6 6 37.3 .58
LDL (mg/dL) 93.3 6 30.8 91.7 6 29.1 98.2 6 36.2 .4
BMI, body mass index; CAD, coronary artery disease; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; Lp(a),
lipoprotein(a); VD, vessel disease; VLDL, very low–density lipoprotein.
Values are given in mean 6 standard deviation for parametric or median (interquartile range) for nonparametric data.
Statin dose: Moderate-to-high dose statin treatment was defined as treatment with atorvastatin with a dosage of at least 40 mg or rosuvastatin at a
dosage of at least 10 mg daily.
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elevated Lp(a) and IM was independent of other lipid param-
eters, risk factors, and statin treatment regime (Table 2).
OxPL on apolipoprotein B-100–containing
lipoproteins is associated with IMs
OxPL/apoB correlated with Lp(a) (R 5 0.43;
P , .0001), and patients with increased Lp(a) showed
significantly higher plasma levels of OxPL/apoB (7647;
IQR, 4192–10915 RLU) as compared with patients with
normal Lp(a) levels (1966; IQR, 1051–4772 RLU;
P , .0001; Fig. 3A). Interestingly, OxPL/apoB showed a
significant correlation with IM (R 5 0.22; P , .05;
Fig. 3B) but not with CM (R 5 20.17; P 5 .13) and
NCM (R 5 0.07; P 5 .53).
Association of circulating inflammatory markers
and Lp(a)
Plasma levels of the acute phase marker CRP were
significantly higher in patients with elevated Lp(a) (0.46;
IQR, 0.12–0.90 mg/dL) as compared with patients with lowLp(a) (0.17; IQR, 0.08–0.46 mg/dL; P 5 .042, Fig. 4).
Patients with Lp(a) .50 mg/dL also showed elevated
plasma levels of the proinflammatory cytokine IL-6 (2.1;
IQR, 1.4–2.8 pg/mL) as compared with patients with
Lp(a) #50 mg/dL (1.5; IQR, 1.0–2.2 pg/mL; P 5 .045).
In contrast, the anti-inflammatory cytokine IL-10 was
not different in patients with high Lp(a) (103.0 6 58.7
pg/mL) as compared with patients with low Lp(a)
(84.5 6 45.3 pg/mL; P 5 .23). Stepwise multivariate linear
regression analysis revealed that the association between
Lp(a) and IM was independent of high-sensitive CRP or
IL-6, respectively.Discussion
In the present study, we provide evidence for the first
time that in patients with stable CAD and elevated serum
levels of the highly proatherogenic Lp(a), monocyte subset
distribution exhibits a more proatherogenic pattern evi-
denced by elevated levels of the proinflammatory subset of
IM, defined as CD1411CD161 cells that has been shown
to be predictive for cardiovascular events.19 This difference
was independent of clinical risk factors such as gender,
Figure 2 Monocyte subset distribution in patients with elevated
lipoprotein(a). The distribution of classical monocytes (A), inter-
mediate monocytes (B), and non-classical monocytes (C) in
patients with normal (#50 mg/dL) and elevated lipoprotein(a)
(.50 mg/dL) were determined as described under Methods. Bar
graphs indicate mean % of total monocytes and error bars repre-
sent standard deviation. *P , .05.
Table 2 Multivariate linear regression model for the
association of lipoprotein(a) and circulating intermediate
monocytes
Parameter Univariate P value b P value
Lp(a) .50 mg/dL .014 0.22 .044
Smoking .024 0.22 .029
LDL cholesterol .053 0.18 .13
Gender .12 0.11 .28
Age .98 0.10 .39
Statin dose .45 20.14 .43
Total model R2 0.17 .018
LDL, low-density lipoprotein.
Statin dose: high-dose statin treatment was defined as treatment
with atorvastatin with a dosage of at least 40 mg or rosuvastatin at a
dosage of at least 10 mg daily.
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influenced by the choice of statin treatment regime. In addi-
tion, we were able to demonstrate that proinflammatory
OxPLs are increased in patients with elevated Lp(a) and
that OxPL/apoB correlated with IM.
Already more than 2 decades ago, heterogeneity among
monocytes was first described by Passlick et al9 using the
surface expression pattern of CD14 and CD16. The newly
described CD16-positive cells received widespread atten-
tion and were soon described as potent proinflammatory
cells as the proportion of these cells was increased in
many diseases with an underlying acute or chronic inflam-
matory stimulus, including atherosclerotic disease.11,12
Furthermore, these cells exhibit a stronger inflammatory
answer after activation with various stimuli.10 About adecade later, by analyzing chemokine receptor expression
on CD16-positive monocytes, Ancuta et al provided evi-
dence for a ‘‘subset in the subset,’’ thus laying the ground
for the distinction between CD1411CD161 and
CD141CD1611 monocytes, which was finally officially
acknowledged in 2010.13,28 The newly termed ‘‘IMs’’
feature a strong inflammatory potential as they strongly
produce reactive oxygen species, IL-1b, and tumor necrosis
factor-a.29,30 In a study including more than 900 stable
CAD patients undergoing elective coronary angiography,
IMs independently predicted cardiovascular events.19
The plasma lipoprotein Lp(a) has been extensively
described as an independent risk factor for both the
development of stable atherosclerotic disease and the
sudden onset of acute ischemic events including myocar-
dial infarction.2,4,31 The underlying pathophysiological
mechanisms for the enhanced atherothrombotic potential
of Lp(a) include a facilitated entrapment within the intima,
promotion of monocyte adhesion to the endothelial
monolayer, an enhanced binding capacity of OxPLs, and
antifibrinolytic and prothrombotic effects.25,32–37 Still,
consensus among the respective cardiovascular societies
on when and in whom to measure Lp(a) and how to react
to elevated levels is missing. The aforementioned European
Atherosclerosis Society Consensus Panel agreed on
measuring Lp(a) once in individuals at high or intermediate
risk for CVD including familial hypercholesterolemia and
in patients with a positive family history of premature
atherosclerotic disease and a 10-y risk of fatal CVD of
3% or more.2 They further recommend a desirable level
for Lp(a) below the 80th percentile, corresponding to less
than 50 mg/dL.
Various cross-sectional and interventional studies in
different patient cohorts demonstrated monocyte subset-
specific interactions with different lipoprotein subclasses.
When comparing findings from today to earlier studies, it
has to be noted that many previous studies only discrim-
inated between CD14-positive and CD16-positive cells as
evidence for a further division of CD16-positive cells was
Figure 3 Association of oxidized phospholipids with lipoprotein(a) levels and intermediate monocytes (IMs). Plasma levels of OxPLP
were determined as described under Methods in patients with normal (#50 mg/dL) and elevated lipoprotein(a) (.50 mg/dL) (A). Corre-
lation of oxidized phospholipid (OxPLP) with IM (B). *P , .0001.
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cross-sectional study, an inverse correlation between
NCM and HDL was shown, whereas a follow-up study of
the same group could not confirm this observation.17,18
However, in the latter study, positive correlations between
NCM and TC, LDL cholesterol, and triglycerides were
observed.18
In our study, when patients were stratified according to
their serum Lp(a) levels above or below the threshold of
50 mg/dL into 2 groups, patients with Lp(a) serum levels
above 50 mg/dL, which corresponds to the 80th percentile
calculated from the Copenhagen General Population
Study,38 demonstrated a striking shift toward a more in-
flammatory monocyte subset distribution. In brief, the pro-
portion of IMs was strongly increased by approximately
35% from 5.2% to 7.0% of all monocytes (P 5 .026). In
contrast, CMs remained unchanged (82% in both groups),
whereas the fraction of NCMs showed a trend toward a
decrease. As evidenced by multivariate regression analysis,
these associations were independent from clinical risk fac-
tors such as gender, age, smoking status, and LDL choles-
terol levels. Furthermore, the choice of statin treatment
regime did not influence the association between Lp(a)
and IMs. This finding is potentially of great interest,Figure 4 Circulating inflammatory markers in patients with normal
(log-scale) (A), interleukin (IL)-6 (log-scale) (B), and IL-10 (C) were
(#50 mg/dL) and elevated lipoprotein(a) (.50 mg/dL). Box plots repras various studies examining a possible effect of statin
treatment on monocyte subset distribution provided con-
flicting results.14,18,39,40
OxPL are proatherogenic by activating proinflammatory
genes, leading to activation of inflammatory cascades
within the arterial wall.20 Recently, it has been shown
that OxPL changes the phenotype of macrophages
in vitro.41 To examine by which mechanism Lp(a) could
shift monocyte subsets toward the proatherogenic distribu-
tion, we measured OxPL bound to apolipoprotein B-100. In
line with previous studies20 that demonstrated that Lp(a) is
a major carrier of OxPL/apoB, we could show that patients
with elevated Lp(a) show increased OxPL/apoB levels. In
addition, OxPL/apoB was associated with IM but not
with CM and NCM suggesting that the shift to a more
proinflammatory monocyte subset distribution in patients
with elevated Lp(a) could possibly be because of its
OxPL content.
Current consensus suggests that in early stages of
atherogenesis, inflammatory activation of the vessel wall
attracts monocytes toward the endothelium causing migra-
tion of monocytes into the subendothelium. Once resident,
they quickly evolve to macrophages starting to take up
(oxidized) phospholipids. Interestingly, macrophages alsoand elevated lipoprotein(a). Plasma levels of C-reactive protein
determined as described under Methods in patients with normal
esent median, interquartile, and total range. *P , .05.
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recognized subsets are the M1 and M2 phenotype. The
classically activated macrophage subset M1 is character-
ized by increased secretion of proinflammatory cytokines,
reactive oxygen species, and tissue degenerating proteins
such as metalloproteinases and was associated with plaque
destabilization and rupture. M2 macrophages on the other
hand are characterized by rather anti-inflammatory and
tissue regenerating effects.8,42 There is currently insuffi-
cient data in the literature whether certain monocyte subsets
evolve into distinct macrophage phenotypes once resident
in the tissue or whether this is characterized by high plas-
ticity. Therefore, one could only speculate whether the
observed association between IM and Lp(a) has any effect
on macrophage subtype distribution within the atheroscle-
rotic plaque, let alone any functional consequences.
Furthermore, only limited data are available on the possible
impact of lipids on macrophage phenotype.43 Interestingly,
in a murine experiment, it was shown that OxPLs skew
macrophages to a phenotype distinct from previously
described phenotypes, termed the Mox phenotype.41 We
therefore refrain from drawing any functional consequences
from our observed associations to macrophage subtype dis-
tribution within the atherosclerotic plaque.
We further analyzed whether patients with elevated
Lp(a) levels demonstrate evidence of elevated chronic
inflammation beyond monocyte subset distribution. Indeed,
we found that these patients have elevated levels of CRP
and IL-6, whereas the anti-inflammatory cytokine IL-10 did
not differ from patients with Lp(a) serum levels below the
threshold. A relation of Lp(a) particle levels with underly-
ing inflammatory activation has been proposed in some
patient cohorts, whereas other studies resulted in conflicting
results.44,45 In a general Caucasian population including
approximately 35,000 individuals, only a very moderate
association between Lp(a) levels and levels of CRP could
be found.46 Interestingly, linear regression analysis revealed
that the association between circulating IM and Lp(a) was
independent of CRP and IL-6 suggesting a possible direct
effect of Lp(a) on monocyte subset distribution. It is of
interest that in a recently published study, IL-6 receptor
expression on CM and IM was increased in CAD patients
when compared with healthy individuals.47
Limitations of the present study include the rather small
number of patients and the cross-sectional study design that
only allows us to describe associations between circulating
immune cells and lipoprotein subfractions, whereas func-
tional insights into the mechanisms underlying this obser-
vation cannot be made. Still, our results provide interesting
insights into the relationship between innate immune
protagonists and a dysregulated lipid status.
To conclude, our results provide evidence for an asso-
ciation between elevated levels of the atherogenic Lp(a)
and an increase of proinflammatory monocytes of the
intermediate subtype in patients with stable atherosclerotic
disease. These findings suggest a potential link between
elevated Lp(a) and activity of innate immunity. Furtherstudies are needed to verify these results and elucidate the
mechanisms underlying these associations.Acknowledgment
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